News & Updates

Hydroxychloroquine does little to prevent pre-eclampsia in pregnant women with lupus

The use of hydroxychloroquine during pregnancy does not appear to reduce the risk of pre-eclampsia among women with systemic lupus erythematosus, as shown in a study.

Robust evidence for fenofibrate in patients with metabolic syndrome on statins

AHA to cardiothoracic surgeons: Get more involved in PE care

A scientific statement endorsed by the American Heart Association (AHA) has urged cardiothoracic surgeons to get more involved in the care of patients at high risk for pulmonary embolism (PE) – and to do it much earlier – to improve outcomes.

Elevated preconception blood pressure linked to adverse pregnancy outcomes

Expectant mothers with high blood pressure (BP) levels before pregnancy are at increased risk of adverse pregnancy outcomes, as reported in a study.

Colchicine beneficial in treatment of myopericarditis

In patients who have had a first attack of pericarditis with evidence of myocardial involvement, treatment with colchicine is safe and helps reduce the risk of recurrence, according to a study.

Overweight, obesity fuel risk of developing cardiopulmonary multimorbidity

Being fat contributes to the development of cardiopulmonary (CP) multimorbidity (MM), reports a study. As a result, adiposity may be targeted by future interventions to help prevent MM.

Young-onset T2D tied to elevated risk of heart failure hospitalization

Individuals who received a diagnosis of type 2 diabetes (T2D) at a young age appear to have a disproportionately increased risk of hospitalization for heart failure (HF), according to a study.

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.